Home
About
Overview
Sharing Data
ORCID
Help
History (3)
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.
Timing and Predictors of Mild and Severe Heat Illness among New Military Enlistees.
See All 3 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.
FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Med. 2013 Aug; 2(4):545-52.
View in:
PubMed
subject areas
Adult
Aged
Antineoplastic Agents
Biomarkers
Carcinoma, Renal Cell
Everolimus
Female
Fluorodeoxyglucose F18
Humans
Kidney Neoplasms
Male
Middle Aged
Neoplasm Metastasis
Positron-Emission Tomography
Sirolimus
Treatment Outcome
Tumor Burden
authors with profiles
Daniel Appelbaum